

BRD2 Antibody


| | |
|----------------------------|---|
| CATALOG NO: | 6281-30T 30 µg (Trial size) 6281-100 100 µg |
| ALTERNATE NAMES: | RING3, RNF3; Bromodomain containing 4 |
| CONCENTRATION: | 0.5 mg/ml |
| HOST: | Rabbit |
| ISOTYPE: | IgG |
| IMMUNOGEN: | Synthetic peptide at N-terminal (BV-M43) |
| PURIFICATION: | Affinity purified rabbit IgG |
| FORM: | Liquid |
| FORMULATION: | 0.5mg/ml in phosphate buffered saline (PBS), pH 7.2, containing 30% glycerol, 0.5% BSA, 5 mM EDTA and 0.03% proclin |
| SPECIES REACTIVITY: | Human, Mouse and Rat. |
| STORAGE CONDITIONS: | Store for 1 year at -20°C from date of shipment. Avoid repeated freeze/thaw cycles. |

DESCRIPTION:

The acetylation of histone lysine residues plays a crucial role in the epigenetic regulation of gene transcription. A bromodomain is a protein domain that recognizes acetylated lysine residues such as those on the N-terminal tails of histones. This recognition is often a prerequisite for protein-histone association and chromatin remodeling. These domains function in the linking of protein complexes to acetylated nucleosomes, thereby controlling chromatin structure and gene expression. Thus, bromodomains serve as “readers” of histone acetylation marks regulating the transcription of target promoters. The BET family of proteins, defined by tandem Bromodomains and an Extra Terminal domain, include BRD2, BRD3, BRD4, and BRDT. The BET proteins play a key role in many cellular processes, including inflammatory gene expression, mitosis, and viral/host interactions. The isolated individual or tandem bromodomains of BRD2 and BRD4 have been shown to bind acetylated histone tails, serving to couple histone acetylation marks to the transcriptional regulation of target promoters. Small molecule inhibitors of these interactions hold promise as useful therapeutics for human disease.

APPLICATION: Western blot: 1:200

Note: This information is only intended as a guide. The optimal dilutions must be determined by the user.



RELATED PRODUCTS:

- Recombinant Human BrdT (22-138 aa) (**Cat. No. 7641-20, 100, -1000**)
- Recombinant Human BRD4 (**Cat. No. 7644-20, 100, -1000**)
- Human recombinant BRD1 bromodomain (**Cat. No. 7645-20, 100**)
- Human recombinant BRD2 bromodomains 1 (**Cat. No. 7646-20, 100**)
- Human recombinant BRD2 bromodomain 1 and 2 (**Cat. No. 7647-20, 100**)
- Human recombinant BRD2 bromodomain 2 (**Cat. No. 7648-20, 100**)
- Human recombinant BRD9 bromodomain (**Cat. No. 7649-20, 100**)
- Bromodomain Inhibitor, (+)-JQ1 (**Cat. No. 2070-1, -5**)
- BRD8 Antibody (**Cat. No. 3738-100**)
- BRD8 Antibody (**Cat. No. 3506-100**)
- BRD8 Blocking Peptide (**Cat. No. 3506BP-50**)
- EZSolution™ (+)-JQ1 (**Cat. No. 2091-1**)
- I-BET151 (**Cat. No. 2220-1, -5**)
- PFI-1 (**Cat. No. 2203-1, -5**)

FOR RESEARCH USE ONLY! Not to be used on humans.